Last update Sept. 4, 2022
It is a prokinetic from the benzamide group, a dopamine antagonist and similar to metoclopramide (Humax 2008). It is used IV, IM and orally every 8 to 12 hours to prevent nausea and vomiting associated with medical and surgical procedures, and cancer therapies
Since the last update we have not found published data on its excretion in breastmilk.
The scarcity of known pharmacokinetic data does not allow to predict the magnitude of its possible excretion in breast milk.
Due to its chemical similarity to metoclopramide, its excretion in breastmilk could be minimal.
Due to its inhibitory effect on dopamine (DrugBank), milk production could increase due to an increase in prolactin. (Minapharm 2014, Humax 2008)
A product with very few bibliographical references and sold in very few countries.
Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM